Viscofan’s BioEngineering unit is the result of the extensive knowledge of the company around collagen and its processing. The creation of this area within the company is based on the conviction that the company must apply its knowledge to help improve welfare and health throughout the community.
Collagen is a protein used in medicine and nutrition, which is providing society with new solutions to health. Viscofan BioEngineering has developed a range of products based in collagen for biomedical and nutrition applications.
In 2017 this division reached an important milestone with the opening of two new plants in Germany (Weinheim) with productive capacity for nutrition and medical markets.
In November the new collagen hydrolysates plant began its operation, which will enable us to produce COLLinstant® for the nutrition market. Collagen hydrolysates are used as a component of nutritional supplements that improve the health of skin, bones and articulations. As the biggest manufacturer of collagen, with COLLinstant® Viscofan will now access this highpotential market.
In May we also inaugurated the medical collagen plant in which we produce the collagen suspension Viscolma® and collagen membranes that are used as coating, as a quality collagen source or as medical implants. BioEngineering works with its customers in the development of medical products with this unique collagen that we have in Viscofan. The new medical plant is equipped with cuttingedge technology to process collagen and will work under a quality management system certified by ISO 13485, which is required for medical products.
An example of the use of solutions developed with Viscofan’s collagen materials is the product VB-C01, which combines a CCC collagen membrane and allogeneic stem cells from fatty tissue to treat patients with heart failure. As of the end of 2017 we requested permission to commence a clinical trial of this product in 2018. This trial will be financed by the Spanish Ministry for the Economy and Competitiveness, and Viscofan works on it through a research consortium with the University of Navarra Hospital, the Hospital Gregorio Marañón of Madrid and the Minimal Invasive Surgery Centre Jesús Usón in Cáceres (Spain).
In 2017 Bioengineering closed as a year with a lot of activity in the installation of capacities, with the aim of achieving better revenue in 2018, which proves the Group’s commitment with diversification as a source of sustainable growth.
We use our own and third-party cookies to improve our services and show you advertising related to your preferences by analyzing your browsing habits. If you go on surfing, we will consider you accepting its use. You can get more information, or know how to change the configuration in our Cookies Policy. Accept